Kornimate/medical-research-clean huggingface dataset:
the relationship between school readiness and sensory processing disorder in preterm preschooler

Conditions: Sensory Deficit; Preterm Birth

Summary: the study aims investigate sensory processing disorders and school readiness in pre-school preterm children and the relationship between sensory impairment and school readiness

a convenience of preterm and term preschoolers recruiting from gazi university, faculty of health science, department of physiotherapy and rehabilitation. each group contains 30 children. first, sociodemographic information and histories of children are obtaining. ages and contact information of the parents are recording. prenatal and natal risk factors of the mothers are querying. gestational ages and height, weight, and head circumferences of babies at birth are recording. number of pregnancies, live births and abortions, type of delivery, multiple pregnancies for mothers as well as consanguinity between parents are asking. marmara primary school readiness scale is using to evaluate mental-language development, socio-emotional development, physical development, self-care skills,math skills, science skills, voice exercises, line exercises and labyrinths. sensory profile caregiver questionnaire screen for the senses (sensory processing), adjustment (modulation), behavioral and emotional responses. . all examination wiil be finished in the same day.

Eligibility criteria:
inclusion criteria: * no neurological diagnosis * gestational age \< 37 weeks * 60-78 months of age exclusion criteria: * have a neurological diagnosis (such as cerebral palsy) * grade iii or grade iv intraventricular hemorrhage * have undergone major surgery in neonatal period * mental retardation

Keywords: preterm sensory processing school readiness
low-dose aspirin for prevention of adverse pregnancy outcomes in twin pregnancies

Conditions: Twin Pregnancy; Preeclampsia; Preterm Birth; Fetal Growth Restriction

Summary: twin pregnancies are associated with increased risk of perinatal adverse outcomes , including preeclampsia , fetal growth restriction , preterm premature rupture of membranes and preterm birth. low-dose aspirin was recommend by american college of obstetricians and gynecologists (acog) during pregnancy. in this trial, the investigators suppose that aspirin used in twin-pregnancies could improve adverse pregnancy outcomes.


Eligibility criteria:
inclusion criteria: * twin pregnancy diagnosed by ultrasound and maternal age ranged from 18 to 55 years, gestational age was less than 16w exclusion criteria: * diagnosed fetal anomalies, history of cervical cerclage, contraindications of aspirin, pre-existing renal or liver diseases or abnormal functions, coagulation disorders, history of pe, preterm birth or fgr, chronic hypertension
noninvasive evaluation of renal allograft fibrosis by mri

Conditions: Kidney Transplantation

Summary: the purpose of this study is to validate an mri method to detect renal fibrosis in patients after kidney transplantation (kt).

the hypothesis underlying this proposal is that qmt reliably detects development of allograft fibrosis in human subjects after kt. to test this hypothesis, the qmt-derived bound pool fraction will be correlated with renal fibrosis as per biopsy in 20 patients 4 or 7 years after living donor kt. the bound pool fraction will also be compared to renal blood flow, oxygenation, and function, and the ability of qmt to provide consistent assessments of fibrosis tested at different magnetic field strengths. two specific aims will test the hypotheses that: specific aim 1: qmt provides reliable and consequential assessment of fibrosis in human kidney allografts. specific aim 2: renal fibrosis assessed by qmt in human kidney allografts is reproducible at 1.5 t and 3.0 t.

Eligibility criteria:
inclusion criteria: * age 18-80 years * recipient of living donor kidney transplantation 4 or 7 years earlier * competent and able to provide written informed consent; ability to comply with protocol exclusion criteria: * patients have clinically significant medical conditions within the prior 6 months before: e.g. myocardial infarction, congestive heart failure, stroke, that would, in the opinion of the investigators, compromise the safety of the patient. * severe chronic liver, heart or lung disease * undergoing acute rejection * contra-indication to biopsy; bleeding disorders * chronic infection * any active malignancy and undergoing therapy * kidney or ureteric stone * unable to give valid informed consent * known pregnancy or intent to conceive during the study period * pacemaker, implantable defibrillator, magnetically active metal fragments, claustrophobia or other contraindication to mri * federal medical center inmates. * latex allergy
dosing of antibiotics during reimplantation of infected knee and hip prostheses

Conditions: Prosthesis-Related Infections

Summary: the purpose of the study is to evaluate the concentrations of antibiotics used as empirical treatment in serum and periprosthetic tissues during reimplantation of infected hip and knee prostheses

the purpose of the study is to evaluate the concentrations of antibiotics (daptomycin, vancomycin, cefotaxime, ceftriaxone, cefepime) in serum and periprosthetic tissues(bone and synovial joint) used as empirical treatment during reimplantation of infected hip and knee prostheses (1-stage or 2-stage management).

Eligibility criteria:
inclusion criteria: * adult patients (aged of 18 years or more) who undergo reimplantation surgery for infected hip or knee prosthesis (performed in 1 or 2-stage(s)), and for whom referral physicians plans to use an empirical antibiotic therapy including cefotaxime, ceftriaxone, cefepime, daptomycin, or vancomycin. exclusion criteria: * patients with multiple prosthetic joint infections, or with curative antibiotic therapy ongoing within two weeks or less prior to surgery, or for whom an antibiotic prophylaxis is decided by referral for the reimplantation surgery, or for whom an antibiotic-loaded cement containing the same antibiotic chosen for empirical therapy after reimplantation was used in case of 2-stage exchange

Keywords: prosthesis-related infections antibiotic dosing reimplantation knee-prothesis hip-prothesis
genetically determined response to atenolol in patients with persistent atrial fibrillation

Conditions: Atrial Fibrillation

Summary: atrial fibrillation (af), the most common sustained heart rhythm disorder, is becoming increasingly prevalent in the western world. the number of people with af in the united states is projected to roughly double by the year 2050, to an estimated 6-12 million. for many patients with af, rate control with atrioventricular (av) node blockers is a widely accepted therapeutic strategy. these agents control heart rate, thus preventing symptoms and systolic heart failure associated with tachycardia due to a rapid ventricular response to af. beta-blockers are widely accepted as first line agents for rate control in af, especially when patients have concomitant hypertension (htn), coronary artery disease, cardiomyopathies, or heart failure (hf). as a class, beta-blockers are among the most commonly prescribed cardiovascular medications. among patients with af treated with beta-blockers, the heart rate (hr) response varies substantially. sometimes, adequate rate control can be achieved by titration of the beta-blocker dose; but frequently, additional av nodal blockers and/or digoxin are necessary. in some cases, adequate rate control cannot be achieved even with the simultaneous use of multiple av nodal blockers, necessitating mechanical ablation of the av node and permanent pacemaker implantation. patient-specific variables that influence the response to beta-blockers include comorbid conditions, weight, age, and level of physical activity. ethnic differences in the response to beta-blockers for the treatment of htn and hf are well-described. however, the contribution of genetic variants to beta-blocker efficacy in af is unknown. we propose to study whether the adrb1 gly389asp snp reduces response to beta-blockade in subjects with permanent af.


Eligibility criteria:
inclusion criteria: * subjects must be at least 18 years of age. * subjects must have a history of persistent af currently treated with a rate control strategy. * subjects should be willing to give written, informed consent. * subjects must be willing and able to participate in the exercise protocol. exclusion criteria: * new york heart association class iii or iv heart failure. * a history of heart failure induced by tachy-arrhythmia. * a history of coronary artery disease and the presence of at least one of the following: * canadian class iii or iv angina. * recent myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention within 6 months. * severe renal or hepatic impairment. * subjects who have a clinically significant allergy/intolerance to atenolol, including a history of beta-blocker induced bronchospasm. * females who are pregnant or nursing. * history of severe av node dysfunction/pacemaker dependence. * subjects who have a systolic blood pressure \ 120 per minute on the day of the study. * patients currently taking vaughan-williams class i or iii anti-arrhythmic drugs.

Keywords: baseline (pre-atenolol) post-atenolol
precise: pancreatic cancer and exercise

Conditions: Pancreas Adenocarcinoma

Summary: the purpose of this study is to establish the feasibility of delivering a prescribed, individualised supervised aerobic and resistance exercise programme during adjuvant therapy, to improve survival and reduce symptom burden in pancreatic cancer

pancreatic ductal adenocarcinoma (pdac) is the most common malignancy of the pancreas, representing 90% of all pancreatic neoplasms. the late presentation of symptoms and a lack of effective screening methods, means a large proportion (80-90%) are diagnosed with unresectable advanced disease, contributing to an unfavorable prognosis and dismal 5-year survival rate of \~5%. intensive cancer treatments (i.e. surgery and chemotherapy) have debilitating complications including fatigue, pain and impaired physical function. therefore, the maintenance of physical function and quality of life are seen as primary treatment goals for pancreatic patients, particularly during adjuvant therapy. exercise training is emerging as an accepted component of patient care and evidence suggests regular exercise may induce an array of physiological and psychosocial benefits. however, there is a lack of evidence on the feasibility of delivering supervised exercise interventions to individuals with resectable pdac undergoing adjuvant therapy. this study aims to explore the initial feasibility of delivering a supervised, individualized, and progressive concurrent exercise intervention to individuals with resectable pdac who are undergoing adjuvant therapy, and provide data required to design a future randomized controlled trials.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * histologically proven pancreatic ductal adenocarcinoma * complete macroscopic resection (r0 or r1 resection) * patients recovering from surgery in time for chemotherapy to be delivered with adjuvant intent * prior malignancy active within the previous 3 years other than locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast * eastern cooperative oncology group (ecog) performance status 0-2 * deemed medically fit by treating team to participate in exercise programme * able to provide informed consent. exclusion criteria: * macroscopically remaining tumour (r2 resection or tumour node metastasis (tnm) stage iv disease) * pre-existing cardiac conditions; congestive heart failure or recent serious cardiovascular event * chest pain while undertaking physical activity * any related co-morbidities (diabetes; unstable angina; degenerative neuromuscular disease; mental health disorders; substance abuse)
fluid responsiveness in posterior fossa tumor resection: ppv and cvp guidance

Conditions: Posterior Fossa Tumor; Brain Tumor Adult

Summary: to answer the question: what are the differences in intraoperative fluid administration volumes between ppv and cvp-guided strategies during posterior fossa tumor resection in the park bench position?

prospective rct is conducted to compared the amount of fluid volume in adult patients undergoing posterior fossa surgery in park bench position.

Eligibility criteria:
inclusion criteria: 1. adult patients aged 18 years and above 2. american society of anesthesiologists (asa) i and ii 3. diagnosis of posterior fossa tumor requiring surgical resection in the park bench position, under general anesthesia at our hospital 4. willing to participate in the study exclusion criteria: 1. arrhythmia 2. significant cardiac diseases 3. chronic obstructive airway disease 4. elevated intra-abdominal pressure 5. tumors prone to precipitate diabetes insipidus 6. peripheral vascular disease 7. pulmonary hypertension 8. patients in sepsis

Keywords: parkbench position posterior fossa tumor pulse pressure variation fluid responsiveness
viagra for the treatment of iugr

Conditions: IUGR

Summary: it has been suggested that viagra (or other drugs that inhibit pde-5, the enzyme that normally inhibits blood vessels' ability to expand) may have beneficial effects in hypertensive pregnancy and, possibly, preeclampsia.the benefits of viagra were observed without any reduction in maternal blood pressure, thereby dissociating hypertension per se from the loss of no (nitrous oxide) signaling in the uterine circulation.following publications, suggesting that sildenafil citrate used as a therapeutic agent may improve myometrial perfusion in iugr gestations by promoting myometrial small artery vasodilatation, decreasing peripheral resistance and increasing flow within the uteroplacental bed, we intend to administer this medication to parturients where intauterine growth restriction and pregnancy associated hypertension have been diagnosed in an attempt to induce vasodilatation and improved uteroplacental perfusion resulting in improved fetal growth.

each participant will receive, after informed consent a 25 mg tablet of viagra \[sildenafil citrate \]orally. the uteroplacental perfusion will be measured using transvaginal and transabdominal ultrasound doppler velocimetry studies, before and after 2, 4, and 24 hours of viagra ingestion. if no significant side effects are recorded, the protocol will be repeated , 48 hours after the first tablet ingestion, but using 50 mg viagra.in cases of positive and encouraging results and if no serious side effects are detected we shall consider repeated administration of the lowest effcetive dose of viagra in an attempt to prevent prematurity and possibly reach term.our study will evaluate the effects of viagra on uterine blood flow changes during pregnancy, and possible changes in other systems that contribute to normal fetal growth and development, in parallel to monitoring general and possible deleterious effects on the retina or other possible maternal or fetal organs.

Eligibility criteria:
inclusion criteria: * iugr/pet/pregnancy weeks 24-33. * informed consent. exclusion criteria: * maternal cardiovascular morbidity. * usage of any vasodilator medication * smoking * diabetes

Keywords: iugr pet pregnancy viagra sildenafil citrate
covid-19 self-testing improve

Conditions: COVID-19

Summary: the study aims to engage community partners to implement improve intervention and promote (covid-19) rapid testing among vulnerable asian americans in the greater philadelphia area and new york city


Eligibility criteria:
inclusion criteria: * (1) self-identified as asian from one of the subgroups: chinese, korean, vietnamese, filipino, or other south asian americans, * (2) aged 18 and above, * (3) living in the greater philadelphia or nyc areas, exclusion criteria: -
comparison of effect of anterior subcutaneous and submuscular transposition on cubital tunnel syndrome

Conditions: Cubital Tunnel Syndrome

Summary: the purpose of this study is to determine which surgical method is better for cubital tunnel syndrome in outcomes.

compression of the ulnar nerve at the cubital tunnel is the most common cause of numbness on the ulnar side of the hand. we aimed to compare patient outcomes included pain, sensation, muscle strength and muscle atrophy in two methods of surgery contain anterior sub cutaneous transposition (asct) and anterior sub muscular transposition (asmt) of the ulnar nerve in cubital tunnel syndrome.

Eligibility criteria:
inclusion criteria: * patients with confirmed cubital tunnel syndrome exclusion criteria: * significant cervical spine and shoulder disease * deformity or distortion of the cubital tunnel due to previous trauma to elbow * recurrent cubital tunnel syndrome after previous surgery.

Keywords: cubital tunnel,subcutaneous transposition,submuscular
phase 1-2a dose-ranging study of tlk286 in combination with docetaxel in platinum-resistant non-small cell lung cancer

Conditions: Carcinoma, Non-small-cell Lung

Summary: the purpose of this study is to determine the effectiveness and safety of tlk286 given intravenously once every three weeks in combination with docetaxel (taxotere) in the treatment of patients with non-small cell lung cancer that is resistant to platinum-based chemotherapy.


Eligibility criteria:
inclusion criteria include: * histologically confirmed non-small cell bronchogenic carcinoma, including squamous cell carcinoma, undifferentiated carcinoma, adenocarcinoma, mixed (adenocarcinoma with squamous cell carcinoma), bronchoalveolar carcinoma, or large cell carcinoma * stage iv or stage iiib * progressed during or after first-line therapies with platinum-containing regimens in the advanced or metastatic treatment regimen * at least 18 years of age * good performance status (ecog 0 to 1) * adequate liver, renal, and bone marrow function exclusion criteria include: * pregnant or lactating women * treatment with more than one cytotoxic therapy * prior radiation to the whole pelvis * unstable medical conditions such as uncontrolled cardiac arrhythmia * patients with known history of severe hypersensitivity reactions to docetaxel or other drugs formulated with polysorbate 80
transcranial photobiomodulation with near-infrared light for language in individuals with down syndrome

Conditions: Down Syndrome

Summary: the aim of this study is to better understand the effects of transcranial photobiomodulation (tpbm) on neural oscillations of individuals diagnosed with down syndrome.

this study will compare the effect of tpbm to sham tpbm on gamma neural oscillations in the brain as assessed by eeg, and on language, attention and memory as assessed by neuropsychological testing. participants will be randomized to either tpbm with near-infrared light (tpbm-nir) or tpbm-sham and will undergo 18 treatments (3 treatments per week for 6 weeks) in addition to baseline, short-term and long- term follow up visits.

Eligibility criteria:
inclusion criteria for this study include: 1. adult men and women between the ages of 16 and 35 2. diagnosis of ds (i.e., clinical diagnosis of trisomy 21 or complete unbalanced translocation of chromosome 21) exclusion criteria for this study include: 1. diagnosis of seizure disorder 2. diagnosis of dementia 3. inability to complete study procedures 4. english as a second language 5. speech as the secondary mode of communication 6. speech of less than two-word utterances 7. changes in medications, augmentative devices, and other intervention two weeks prior to baseline testing and throughout study completion at pi's discretion 8. untreated obstructive sleep apnea (osa) 9. participation in other clinical research trials that may influence affect primary outcomes or adherence to the proposed study, as assessed by the pi and the co-is 10. candidates who have a current diagnosis of cancer and/or are currently undergoing treatment for cancer 11. history of migraine with an aura in the past 6 months 12. current pregnancy
pharmacogenomic testing to personalize supportive oncology

Conditions: Cancer; Depression; Pain

Summary: the purpose of this study is to evaluate pharmacogenomics (pgx) guided drug prescribing for pain and depression in patients with cancer. the investigators aim to understand how pgx testing can be used to improve medication management for pain and depression, and whether pgx-guided prescribing improves these symptoms and quality of life compared to historical controls.

this is a prospective clinical trial of adult cancer patients presenting with pain and depression, newly referred to the department of supportive oncology, and receiving preemptive pgx testing for genes related to supportive care prior to the first clinic visit. genotyping results will be returned within approximately 4-5 business days. a pgx specialist will provide detailed clinical interpretations to the referring provider and upload a copy of the test results into the subject's medical chart. a consultation note will also be placed in each subject's chart detailing the pgx results. supportive oncology clinicians will be instructed to consult a pharmacist to evaluate pgx test results prior to prescribing supportive care therapies, especially pain and depression medications. the number of consults and recommendations will be documented, in addition to test results, demographic data, medical/medication history, esas symptom scores, phq9 depression scores, and side effects of supportive therapy. the number of ambulatory clinic visits and hospitalizations will be used to estimate health care utilization and costs. subjects will complete a short survey at the end of the study period regarding their knowledge about pgx, and whether access to pgx information improves satisfaction with care and communication.

Eligibility criteria:
inclusion criteria * written informed consent and hipaa authorization for release of personal health information. * completion of esas at initial palliative medicine clinic visit, presenting with moderate to high pain (≥ 4/10) and/or depression (≥ 3/10). * new patients ≥ 18 years of age who have had an initial visit in the department of supportive oncology's palliative medicine clinic with hematologic malignancy or any stage solid tumor malignancy according to the provider. * agree to at least one additional palliative medicine clinic visit per protocol. * able to provide a buccal sample for pgx testing. exclusion criteria * psychiatric illness, social situations, or active/recent (within 30 days) history of illicit substance (e.g. cocaine, heroin) abuse that would limit compliance with study requirements (e.g. clinic visits, medication compliance, etc.) as determined by the investigator. * patients who have had prior multiple visits in palliative medicine clinic.